86 related articles for article (PubMed ID: 12873990)
1. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues.
Gorden A; Osman I; Gai W; He D; Huang W; Davidson A; Houghton AN; Busam K; Polsky D
Cancer Res; 2003 Jul; 63(14):3955-7. PubMed ID: 12873990
[TBL] [Abstract][Full Text] [Related]
2. Preponderance of the oncogenic V599E and V599K mutations in B-raf kinase domain is enhanced in melanoma cutaneous/subcutaneous metastases.
Deichmann M; Thome M; Benner A; Kirschner M; Hassanzadeh J; Kurzen H
BMC Cancer; 2005 Jun; 5():58. PubMed ID: 15935100
[TBL] [Abstract][Full Text] [Related]
3. Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma.
Greaves WO; Verma S; Patel KP; Davies MA; Barkoh BA; Galbincea JM; Yao H; Lazar AJ; Aldape KD; Medeiros LJ; Luthra R
J Mol Diagn; 2013 Mar; 15(2):220-6. PubMed ID: 23273605
[TBL] [Abstract][Full Text] [Related]
4. Oncogene-like addiction to aneuploidy in human cancers.
Girish V; Lakhani AA; Scaduto CM; Thompson SL; Brown LM; Hagenson RA; Sausville EL; Mendelson BE; Lukow DA; Yuan ML; Kandikuppa PK; Stevens EC; Lee SN; Salovska B; Li W; Smith JC; Taylor AM; Martienssen RA; Liu Y; Sun R; Sheltzer JM
bioRxiv; 2023 Jan; ():. PubMed ID: 36711674
[TBL] [Abstract][Full Text] [Related]
5. Vemurafenib Combined With Trametinib Significantly Benefits the Survival of a Patient With Stage IV Pancreatic Ductal Adenocarcinoma With BRAF V600E Mutation: A Case Report.
Wang Z; He D; Chen C; Liu X; Ke N
Front Oncol; 2021; 11():801320. PubMed ID: 35145907
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory conversion of quiescent osteoblasts by metastatic breast cancer cells through pERK1/2 aggravates cancer-induced bone destruction.
Back J; Nguyen MN; Li L; Lee S; Lee I; Chen F; Gillinov L; Chung YH; Alder KD; Kwon HK; Yu KE; Dussik CM; Hao Z; Flores MJ; Kim Y; Ibe IK; Munger AM; Seo SW; Lee FY
Bone Res; 2021 Sep; 9(1):43. PubMed ID: 34588427
[TBL] [Abstract][Full Text] [Related]
7. Novel insights into the pathogenesis and treatment of NRAS mutant melanoma.
Zhao J; Galvez C; Beckermann KE; Johnson DB; Sosman JA
Expert Rev Precis Med Drug Dev; 2021; 6(4):281-294. PubMed ID: 34485698
[TBL] [Abstract][Full Text] [Related]
8. Defining and Targeting BRAF Mutations in Solid Tumors.
Halle BR; Johnson DB
Curr Treat Options Oncol; 2021 Feb; 22(4):30. PubMed ID: 33641072
[TBL] [Abstract][Full Text] [Related]
9. Selective antagonism of cJun for cancer therapy.
Brennan A; Leech JT; Kad NM; Mason JM
J Exp Clin Cancer Res; 2020 Sep; 39(1):184. PubMed ID: 32917236
[TBL] [Abstract][Full Text] [Related]
10. New Insights into the Role of Sphingolipid Metabolism in Melanoma.
Carrié L; Virazels M; Dufau C; Montfort A; Levade T; Ségui B; Andrieu-Abadie N
Cells; 2020 Aug; 9(9):. PubMed ID: 32858889
[TBL] [Abstract][Full Text] [Related]
11. Role of Melanin Chemiexcitation in Melanoma Progression and Drug Resistance.
Premi S
Front Oncol; 2020; 10():1305. PubMed ID: 32850409
[TBL] [Abstract][Full Text] [Related]
12. CRISPR Screens Identify Essential Cell Growth Mediators in BRAF Inhibitor-resistant Melanoma.
Li Z; Wang B; Gu S; Jiang P; Sahu A; Chen CH; Han T; Shi S; Wang X; Traugh N; Liu H; Liu Y; Wu Q; Brown M; Xiao T; Boland GM; Shirley Liu X
Genomics Proteomics Bioinformatics; 2020 Feb; 18(1):26-40. PubMed ID: 32413516
[TBL] [Abstract][Full Text] [Related]
13. Emerging strategies to treat rare and intractable subtypes of melanoma.
Alicea GM; Rebecca VW
Pigment Cell Melanoma Res; 2021 Jan; 34(1):44-58. PubMed ID: 32274887
[TBL] [Abstract][Full Text] [Related]
14. Management of intracranial melanomas in the era of precision medicine.
Young GJ; Bi WL; Wu WW; Johanns TM; Dunn GP; Dunn IF
Oncotarget; 2017 Oct; 8(51):89326-89347. PubMed ID: 29179523
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological Inhibition of Myocardin-related Transcription Factor Pathway Blocks Lung Metastases of RhoC-Overexpressing Melanoma.
Haak AJ; Appleton KM; Lisabeth EM; Misek SA; Ji Y; Wade SM; Bell JL; Rockwell CE; Airik M; Krook MA; Larsen SD; Verhaegen M; Lawlor ER; Neubig RR
Mol Cancer Ther; 2017 Jan; 16(1):193-204. PubMed ID: 27837031
[TBL] [Abstract][Full Text] [Related]
16. Negative feedback regulation of the ERK1/2 MAPK pathway.
Lake D; Corrêa SA; Müller J
Cell Mol Life Sci; 2016 Dec; 73(23):4397-4413. PubMed ID: 27342992
[TBL] [Abstract][Full Text] [Related]
17. BRAF mutation may have different prognostic implications in early- and late-stage colorectal cancer.
Chen KH; Lin YL; Liau JY; Tsai JH; Tseng LH; Lin LI; Liang JT; Lin BR; Hung JS; Chang YL; Yeh KH; Cheng AL
Med Oncol; 2016 May; 33(5):39. PubMed ID: 27034263
[TBL] [Abstract][Full Text] [Related]
18. Molecular alterations in clinical stage III cutaneous melanoma: Correlation with clinicopathological features and patient outcome.
Rutkowski P; Gos A; Jurkowska M; Switaj T; Dziewirski W; Zdzienicki M; Ptaszyński K; Michej W; Tysarowski A; Siedlecki JA
Oncol Lett; 2014 Jul; 8(1):47-54. PubMed ID: 24959217
[TBL] [Abstract][Full Text] [Related]
19. Pyrazolopyridine Inhibitors of B-Raf(V600E). Part 1: The Development of Selective, Orally Bioavailable, and Efficacious Inhibitors.
Wenglowsky S; Ren L; Ahrendt KA; Laird ER; Aliagas I; Alicke B; Buckmelter AJ; Choo EF; Dinkel V; Feng B; Gloor SL; Gould SE; Gross S; Gunzner-Toste J; Hansen JD; Hatzivassiliou G; Liu B; Malesky K; Mathieu S; Newhouse B; Raddatz NJ; Ran Y; Rana S; Randolph N; Risom T; Rudolph J; Savage S; Selby LT; Shrag M; Song K; Sturgis HL; Voegtli WC; Wen Z; Willis BS; Woessner RD; Wu WI; Young WB; Grina J
ACS Med Chem Lett; 2011 May; 2(5):342-7. PubMed ID: 24900315
[TBL] [Abstract][Full Text] [Related]
20. Targeted BRAF inhibition impacts survival in melanoma patients with high levels of Wnt/β-catenin signaling.
Chien AJ; Haydu LE; Biechele TL; Kulikauskas RM; Rizos H; Kefford RF; Scolyer RA; Moon RT; Long GV
PLoS One; 2014; 9(4):e94748. PubMed ID: 24733413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
